Harold Edward Bays
Harold Edward Bays
Image 1. © 2025 The Author.
Outcomes of obesity medications in those with low response to a low-energy diet meal replacement programme: An observational study [0.03%]
肥胖低反应者在接受低能量饮食代餐计划后的减肥药物疗效观察性研究
James Shand,Yannan Jiang,Rinki Murphy
James Shand
Background: It is not known how individuals respond to liraglutide or naltrexone/bupropion following low-response to a structured meal replacement low energy diet (MR-LED) programme. ...
John T Stutts,Yong S Choe,Ashley Lynn Bronston
John T Stutts
Background: Adolescence is a critical period of growth with elevated nutritional demands, yet many U.S. adolescents fail to meet recommended dietary intakes. This study analyzed data from three NHANES cycles (2013-2018) t...
Laparoscopic sleeve gastrectomy in a patient with type 1 diabetes and kidney transplant: A case report [0.03%]
1例1型糖尿病肾移植患者的袖状胃切除术：病例报告
María José Ayora-Pérez,Eduardo Andrés Román Cataña,Bernarda Patiño-Araujo et al.
María José Ayora-Pérez et al.
Introduction: Obesity in patients with type 1 diabetes mellitus (T1DM) and kidney disease presents unique challenges, particularly after transplantation, where weight gain can compromise graft function and metabolic contr...
Case Reports
Obesity pillars. 2025 Dec 16:17:100243. DOI:10.1016/j.obpill.2025.100243 2025
Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach [0.03%]
基于GLP-1的肥胖症治疗管理中营养和生活方式支持性护理建议专家共识声明（德尔菲法修正版）
J L Sievenpiper,J Ard,M Blüher et al.
J L Sievenpiper et al.
Background: Liraglutide, semaglutide and tirzepatide have transformed the management of obesity. However, dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and poor long-term adherence...
Reporting the effectiveness of dietary intervention on weight loss outcomes in patients with obesity and overweight: a retrospective chart review at a Center of Excellence in UAE [0.03%]
在阿联酋卓越中心进行的肥胖和超重患者饮食干预减重效果的回顾性病历分析报告
Mona Joumaa,Madeeha Kalsekar,Momina Malik et al.
Mona Joumaa et al.
Background: A modest weight loss of ≥5 % among patients with obesity is associated with a reduced risk of type 2 diabetes, hypertension, and other obesity-related complications. Dietary interventions play a central role ...
Association of Ethiopian Orthodox Tewahedo Christian fasting on appetite hormones and insulin sensitivity in type-II diabetes and healthy subjects in Ethiopia [0.03%]
埃塞俄比亚东正教徒的斋戒对2型糖尿病和健康受试者食欲激素及胰岛素敏感性的影响
Alemayehu Michael,Kaleab Baye
Alemayehu Michael
Background: Energy restriction, time-restricted feeding, and vegetarian diet intake each have been linked independently to positive health effects. However, little is known about the religious fasts practiced by Ethiopian...
Applicability of the New Zealand-eating behavior questionnaire to predict weight loss responses to naltrexone/bupropion: a proof-of-concept trial [0.03%]
新西兰饮食行为问卷预测诺马贝龙预测减重反应的适用性：概念验证试验
Ole Schmiedel,Melissa Ivey,Nishi Karunasinghe et al.
Ole Schmiedel et al.
Background: Despite the availability of different obesity medications, individual responses vary widely. This pilot study evaluated whether the New Zealand Eating Behavior Questionnaire (NZ-EBQ) could predict weight loss ...
Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol [0.03%]
利用个体化虚拟整合医学协议进行 tirzepatide 治疗的体重减轻和治疗依从性研究
Jessica Duncan,Patrick Lee Stevens,Emily Bigby et al.
Jessica Duncan et al.
Introduction: Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agoni...
Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it [0.03%]
GLP-1受体激动剂减重药物降低性欲的临床分析及我们未能“发现”该作用的生物心理社会学模型
Sonya T Gelfand,Meghan C Tveit,James A Simon
Sonya T Gelfand
Background: While prevailing assumptions suggest that improved body image and erectile function, even in people with diabetes, associated with glucagon-like peptide-1 (GLP-1) agonist medications would correlate with heigh...